医学
美罗华
阿巴塔克普
临床试验
肌炎
重症监护医学
贾纳斯激酶
托法替尼
生物制剂
药品
内科学
类风湿性关节炎
药理学
淋巴瘤
细胞因子
作者
Ana Neves,Luísa Viveiros,Veronica Venturelli,David Isenberg
出处
期刊:Rheumatology
[Oxford University Press]
日期:2024-02-06
被引量:1
标识
DOI:10.1093/rheumatology/keae096
摘要
Abstract Idiopathic inflammatory myopathies (IIMs) are a rare and heterogeneous group of chronic autoimmune disorders. Up to 40% of IIM patients have long-term sequelae and significant functional disability. Its management can be challenging and new therapies are badly needed. The small number of cases with diverse presentations and different diagnostic criteria significantly affect clinical trial results. Only IVIG has been internationally approved for IIM patients. Most clinical trials of new biologic therapies have failed to meet their primary endpoints in IIM, with only one biologic drug recommended for refractory IIM treatment (rituximab), although not approved. We review several new emerging biologic drugs, including B cell depletion therapies, abatacept, Janus kinase inhibitors, and aldesleukin. Encouragingly, some phase II randomized controlled trials have evaluated the efficacy and safety of new biologics in IIM, demonstrating an improvement in clinical and laboratory measures.
科研通智能强力驱动
Strongly Powered by AbleSci AI